The McManus Group represents some of the most notable
and respected health care companies and associations
in the country.

Alnylam Pharmaceuticals, headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. Founded in 2002, Alynlam has potential treatments in various development stages in Genetic Medicine, Cardio-Metabolic Disease, and Hepatic Infectious Disease. Alnylam’s pipeline drug Patisiran received FDA approval in 2018, and Fitusiran, Inclisiran, and Givosiran are expected to be approved by 2019. Other drugs including Cemdisiran, ALN-GO1, and ALN-TTRsc02 are potentially expected to be approved by 2020.

The Ambulatory Surgery Center Association represents more than 11,000 facilities and corporate ambulatory surgery centers (ASCs), which provide a high quality and less expensive alternative for outpatient surgery than outpatient hospital departments.

MEDNAX, Inc. is a national medical group that comprises the nation’s leading provider of neonatal, maternal-fetal and pediatric physician subspecialty services as well as anesthesia services.

The Large Urology Group Practice Association represents large urology physician practices that provide comprehensive and integrated urological care for patients with prostate cancer and other ailments.

The Digestive Health Physicians Association represents independent gastroenterology (GI) physician practices with the aim of promoting and preserving the integrated model of healthcare delivery.

AOTA represents the interests and concerns of 213,000 occupational therapy practitioners and students. AOTA’s members are concerned about Medicare policy that hampers access to therapy care for the sickest seniors.

IVX Health, headquartered in Brentwood, Tennessee, provides high-quality biologic injections and infusions in private and comfortable facilities. Their services treat a range of chronic and subacute non-infectious conditions such as rheumatoid arthritis, lupus, multiple sclerosis, and many more at 13 locations nationwide. Formerly Infusion Express, the company completed a $22.5 million round of funding in August 2019, which will help accelerate its national growth.

The National Association of Freestanding Emergency Centers (NAFEC) represents the spectrum of FECs, including independent, hospital-owned, and hybrid models alike. They were established to advocate for fair regulation and to raise statewide awareness of freestanding emergency centers as a high-quality, accessible, emergency medical care option.

Gilead Sciences, Inc., located in Foster City, CA, is a research-based biopharmaceutical company that is a leader in treatments for HIV/AIDS, liver diseases, serious respiratory and cardiovascular conditions, cancer and inflammation. Gilead’s 2018 revenues were over $22 billion.

Royalty Pharma has created a rapidly growing company within the biopharmaceutical industry through the acquisition of revenue producing intellectual property – principally, royalty interests in marketed and late stage development biopharmaceutical products. Royalty Pharma has been working with research institutions, inventors and biotechnology & pharmaceutical companies since 1996, and now owns royalty interests in 31 approved and marketed biopharmaceutical products and 7 products in clinical trials and/or under review with the United States Food and Drug Administration (“FDA”) and/or the European Medicines Agency (“EMA”).

Headquartered in Seal Beach, California, Dendreon Pharmaceuticals develops immunotherapies to treat cancer. Its flagship product, Provenge, approved to treat prostate cancer in 2010, has been prescribed to over 30,000 patients. In 2017, Provenge sales topped $330 million.

PhRMA, the Pharmaceutical Research and Manufacturers of America, represents leading research-based pharmaceutical companies in the US.

Located in South San Francisco, Genentech is a leader in cancer care and treatments include Avastin, Actemra, Tacerva, Lucentis, Erivedge, PERJETA, and Kadcyla. Now owned by Roche Holdings, the company employs nearly 14,000 people.

EMD Serono, Inc. is a German based company with more than 1,000 employees throughout the United States headquartered in Rockland, Massachusetts. EMD Serono has more than 20 trials in their global clinical pipeline, focused on developing innovative therapies for cancer and neurodegenerative diseases such as multiple sclerosis and Parkinson’s disease.

Horizon Pharma plc is a biopharmaceutical company focused developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. Horizon’s products include Duexis, to relieve arthritic pain and prevent gastric ulcers, and Vimovo, to relieve arthritic pain and ankylosing spondylitis.

Zimmer Biomet, headquartered in Warsaw, Indiana, is a global leader in musculoskeletal healthcare. They design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

The Medical Device Manufacturers Association (MDMA) is a national trade association based in Washington, DC providing educational and advocacy assistance to innovative and entrepreneurial medical technology companies. It is focused on repealing the medical device excise tax and reducing the regulatory border to device companies.

Based in Menlo Park, CA, GRAIL is a clinical-stage diagnostics company developing a multi-cancer blood test for detection of more than 50 types of cancer across early and late stages. The test also aims to detect an individual’s cancer tissue of origin to guide physicians and patients toward a faster, more efficient, and most appropriate treatment.

At WEX Health, we simplify the business of healthcare. We do that through WEX Health Cloud, a cloud-based healthcare financial management platform that drives efficiency for benefit administration technology, consumer engagement, and advanced billing and payments. Our network of partner organizations enables us to deliver our industry-leading and award-winning solution to 200,000 employers and more than 17 million consumers across the United States and Canada. Together we take the complexity out of defined contribution, HSAs, HRAs, FSAs, VEBAs, PRAs, premium billing, public and private health insurance exchanges, COBRA, wellness plans, and transit plans.

Current clients include the following (please contact our office for a complete client list):


The McManus Group
610 10th St. NW
Washington , DC , 20001
(202) 383-0085